Literature DB >> 9373237

Fusion of the platelet-derived growth factor receptor beta to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution.

A Abe1, N Emi, M Tanimoto, H Terasaki, T Marunouchi, H Saito.   

Abstract

Chromosomal translocations involving band 5q31-35 occur in several hematologic disorders. A clone with a t(5; 14)(q33; q32) translocation appeared at the relapse phase in a patient with acute myelogenous leukemia who exhibited a sole chromosomal translocation, t(7; 11), at initial diagnosis. After the appearance of this clone, the leukemia progressed with marked eosinophilia, and combination chemotherapy was ineffective. Southern blot analysis showed a rearrangement of the platelet-derived growth factor receptor beta (PDGFRbeta) gene at 5q33 which was not observed at initial diagnosis. This translocation resulted in a chimeric transcript fusing the PDGFRbeta gene on 5q33 with a novel gene, CEV14, located at 14q32. Expression of the 5' region of the PDGFRbeta cDNA, upstream of the breakpoint, was not detected. However, the 3' region of PDGFRbeta, which was transcribed as part of the CEV14-PDGFRbeta fusion gene, was detected. A partial cDNA for a novel gene, CEV14, includes a leucine zipper motif and putative thyroid hormone receptor interacting domain and is expressed in a wide range of tissues. The expression of a CEV14-PDGFRbeta fusion gene in association with aggressive leukemia progression suggests that this protein has oncogenic potential.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9373237

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia.

Authors:  Q Liu; J Schwaller; J Kutok; D Cain; J C Aster; I R Williams; D G Gilliland
Journal:  EMBO J       Date:  2000-04-17       Impact factor: 11.598

2.  Cloning and characterization of a novel druggable fusion kinase in acute myeloid leukemia.

Authors:  Christian Michel; Elisabeth K.M. Mack; Christopher-Nils Mais; Lea V Fritz; Ying Wang; Lutz B. Jehn; Sonja K. Hühn; Clara Simon; Sabrina Inselmann; André Marquardt; Jennifer Kremer; Ellen Wollmer; Kristina Sohlbach; Andreas Neubauer; Cornelia A. Brendel; Claudia Haferlach; Gert Bange; Andreas Burchert
Journal:  Haematologica       Date:  2019-12-02       Impact factor: 9.941

Review 3.  STAT signaling in the pathogenesis and treatment of cancer.

Authors:  D A Frank
Journal:  Mol Med       Date:  1999-07       Impact factor: 6.354

4.  Fusion of platelet-derived growth factor receptor β to CEV14 gene in chronic myelomonocytic leukemia: A case report and review of the literature.

Authors:  Sheng-Lan Gong; Meng-Qiao Guo; Gu-Sheng Tang; Chun-Ling Zhang; Hui-Ying Qiu; Xiao-Xia Hu; Jian-Min Yang
Journal:  Oncol Lett       Date:  2015-11-18       Impact factor: 2.967

5.  CASP, the alternatively spliced product of the gene encoding the CCAAT-displacement protein transcription factor, is a Golgi membrane protein related to giantin.

Authors:  Alison K Gillingham; Andrea C Pfeifer; Sean Munro
Journal:  Mol Biol Cell       Date:  2002-11       Impact factor: 4.138

Review 6.  Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis.

Authors:  Ayalew Tefferi; Animesh Pardanani
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

Review 7.  Current treatment options: impact of cytogenetics on the course of myelodysplasia.

Authors:  Naomi Galili; Jan Cerny; Azra Raza
Journal:  Curr Treat Options Oncol       Date:  2007-04

8.  Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.

Authors:  John H Griffin; Joey Leung; Rebecca J Bruner; Michael A Caligiuri; Roger Briesewitz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-13       Impact factor: 11.205

Review 9.  BCR-ABL-negative chronic myeloid leukemia.

Authors:  Sonja Burgstaller; Andreas Reiter; Nicholas C P Cross
Journal:  Curr Hematol Malig Rep       Date:  2007-05       Impact factor: 4.213

10.  The Golgin GMAP210/TRIP11 anchors IFT20 to the Golgi complex.

Authors:  John A Follit; Jovenal T San Agustin; Fenghui Xu; Julie A Jonassen; Rajeev Samtani; Cecilia W Lo; Gregory J Pazour
Journal:  PLoS Genet       Date:  2008-12-26       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.